Double Your Innovation Impact at TIDES Europe
Register for TIDES Europe and add on exclusive access to Obesity Science & Innovation Europe
Two premier conferences, one powerful experience
A Snapshot of the Obesity Science & Innovation Europe 2026 Agenda
GLP-1 & Next-Generation Multi-Agonist Therapies
Exploring clinical updates from leading GLP-1, dual, and triple agonist programs across peptide and small molecule modalities, including efficacy data and novel oral formulations addressing limitations of injectable therapies.
RNA-Based Approaches
Exploring RNA-based approaches for obesity, including siRNA-mediated inhibition of metabolic targets and non-coding RNA technologies with insights from Phase 1 clinical data.
European Market Access & Commercialization Strategies
Navigating regulatory pathways, reimbursement frameworks, and market access challenges to successfully translate innovative obesity therapeutics into commercially viable solutions across diverse European healthcare systems.
Investment, Valuation & Strategic Partnerships
Examining valuation trends, licensing opportunities, and strategic collaborations shaping the obesity therapeutics landscape, with insights from leading investors, pharma BD&L teams, and emerging biotech innovators.
Digital Health Integration
Integrating digital health solutions with obesity therapeutics to enhance patient engagement, treatment adherence, and real-world outcomes through connected technologies and data-driven personalization.
Dedicated Networking Hours
Connect with pharmaceutical executives, biotech innovators, clinical researchers, and investors during structured networking breaks designed to foster collaboration, exchange insights, and build strategic partnerships across the obesity innovation ecosystem.
Why Attend Both TIDES Europe and OSI Europe?
The convergence of advanced therapeutic modalities and metabolic health innovation is reshaping drug development. From oligonucleotide-based RNA therapies to GLP-1 peptides, the technologies driving TIDES Europe are directly enabling the obesity breakthroughs showcased at OSI EU.
One City, Two Transformative Events
Both conferences take place in Amsterdam during the same week. Move effortlessly from exploring oligonucleotide and peptide innovations at RAI Amsterdam Convention Centre to diving deep into obesity therapeutics at nhow Amsterdam RAI all within the same city.
The Modality-to-Application Connection
TIDES Europe brings you the foundational science: oligonucleotide chemistry, peptide design, mRNA development, drug delivery systems, and CMC strategies from 900+ industry experts.
OSI EU shows you these modalities in action: GLP-1 peptide therapies, siRNA-mediated metabolic targeting, RNA-based obesity approaches, and next-generation multi-agonist treatments transforming patient outcomes.
Expanded Networking Across the Value Chain
Connect with 1,000+ pharmaceutical executives, biotech innovators, clinical researchers, and investors across both events. Build relationships spanning from discovery scientists optimizing oligonucleotide chemistry to commercial leaders navigating European market access for obesity therapeutics.
European Market Focus
Both events emphasize the European landscape. TIDES Europe highlights regional manufacturing and regulatory strategies for advanced modalities, while OSI EU provides actionable insights on reimbursement frameworks, pricing strategies, and commercialization pathways specific to diverse European healthcare systems.
Strategic Advantage for Multiple Stakeholders
For R&D Teams: Understand how oligonucleotide and peptide platforms translate into breakthrough obesity treatments
For Business Development: Identify licensing opportunities and partnership potential across modality development and therapeutic application
For Investors: Evaluate the full value chain from platform technology to commercial viability in one of healthcare's fastest-growing markets
For Clinical Teams: Connect preclinical innovation with clinical trial design and real-world evidence generation
Cross-Pollinate Expertise
Gain dual perspectives on therapeutic innovation:
- Technical depth at TIDES Europe: CMC efficiency, formulation strategies, delivery optimization, and manufacturing scale-up
- Clinical and commercial application at OSI EU: Real-world efficacy data, patient adherence strategies, regulatory approval pathways, and investment trends